Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density.
Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Dimopoulou M, Komninaka V, Repa K, Papatheodorou A, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Ann Hematol. 2019 Jul;98(7):1583-1592. doi: 10.1007/s00277-019-03695-x. Epub 2019 Apr 30. Ann Hematol. 2019. PMID: 31041514 Clinical Trial.
High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Horm Metab Res. 2012 Nov;44(12):909-13. doi: 10.1055/s-0032-1312618. Epub 2012 May 11. Horm Metab Res. 2012. PMID: 22581647 Clinical Trial.
Denosumab effects on serum levels of the bone morphogenetic proteins antagonist noggin in patients with transfusion-dependent thalassemia and osteoporosis.
Voskaridou E, Ntanasis-Stathopoulos I, Christoulas D, Sonnleitner L, Papaefstathiou A, Dimopoulou M, Missbichler A, Kanellias N, Repa K, Papatheodorou A, Peppa M, Hawa G, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Hematology. 2019 Dec;24(1):318-324. doi: 10.1080/16078454.2019.1570617. Hematology. 2019. PMID: 30665323 Free article. Clinical Trial.
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA. Terpos E, et al. Among authors: christoulas d. Ann Oncol. 2012 Oct;23(10):2681-2686. doi: 10.1093/annonc/mds068. Epub 2012 Apr 6. Ann Oncol. 2012. PMID: 22492699 Free article.
Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.
Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Haematologica. 2009 May;94(5):725-8. doi: 10.3324/haema-tol.2008.000893. Haematologica. 2009. PMID: 19407319 Free PMC article.
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. Voskaridou E, et al. Among authors: christoulas d. Blood. 2010 Mar 25;115(12):2354-63. doi: 10.1182/blood-2009-05-221333. Epub 2009 Nov 10. Blood. 2010. PMID: 19903897 Free article. Clinical Trial.
Pathogenesis and management of myeloma bone disease.
Christoulas D, Terpos E, Dimopoulos MA. Christoulas D, et al. Expert Rev Hematol. 2009 Aug;2(4):385-98. doi: 10.1586/ehm.09.36. Expert Rev Hematol. 2009. PMID: 21082944 Review.
71 results